Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.79 |
| ▸ | RAF1 | P04049 | 2/20 | 0.79 |
| ▸ | LYN | P07948 | 2/20 | 0.79 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.79 |
| ▸ | BRAF | P15056 | 1/20 | 0.79 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.79 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.79 |
| ▸ | AKT1 | P31749 | 1/20 | 0.79 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.73 |
| ▸ | SRC | P12931 | 8/20 | 0.58 |
| ▸ | GSK3A | P49840 | 8/20 | 0.47 |
| ▸ | SCARB1 | Q8WTV0 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 7/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6779542 | 0.93 | ABL1 (0.77) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6614260 | 0.92 | ABL1 (0.67) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6599887 | 0.91 | ABL1 (0.80) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6609488 | 0.91 | ABL1 (0.84) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL4091655 | 0.91 | ABL1 (0.84) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL14376097 | 0.91 | ABL1 (0.84) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6611338 | 0.90 | ABL1 (0.79) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6053406 | 0.90 | ABL1 (0.82) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6609379 | 0.90 | ABL1 (0.78) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL4091842 | 0.89 | ABL1 (0.82) | ABL1RAF1LYNMAPK9EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743788-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; AUTOIMMUNE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-01 | — | — | US | claimed |
| US-20030092702-A1 | Novel carbamate and oxamide compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | US | claimed |
| US-6743788-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; AUTOIMMUNE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-01 | — | — | US | disclosed |
| EP-1395561-A1 | CARBAMATE AND OXAMIDE COMPOUNDS AS INHIBITORS OF CYTOKINE PRODUCTION | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002096876-A1 | CARBAMATE AND OXAMIDE COMPOUNDS AS INHIBITORS OF CYTOKINE PRODUCTION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092702-A1 | Novel carbamate and oxamide compounds | IFNG, CXCR1, ARG1 | ABL1 3489/4885RAF1 3121/4885LYN 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.